Brii Biosciences Ltd. - B Stock: price and insider trades · Hong Kong
2 insiders bought shares over the last 90 days, the latest by Hong Zhi, filed 30 Oct 2026.
Cluster: 2 buyers in 30 daysBrii Biosciences Ltd. - B: what insiders have been doing
Brii Biosciences Ltd. - B belongs to the Health Care sector. Filings by its managers are published through HKEX. The last twelve months, up to 30 October 2026, brought 14 filings signed by 2 insiders.
Open-market activity splits into 2 purchases and 4 sales totalling €7,956; 2 insiders sit on the buying side and 1 insider on the selling side. No amount is published for 3 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a sale of €4,142 from Li Ankang, disclosed on 25 September 2026, or 0.0057% of market capitalisation. Those buying include 2 senior executives.
Compared with its exchange (1,319 companies, median 4 filings), a count of 14 filings is above the norm. Over the whole record (from 2021), the tally stands at 37 purchases and 15 sales.
The latest purchase is recent: it was published 9 days ago, on 30 October 2026. Typically, a trade is published a median of 3 days after it takes place. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Source: insider filings from HKEX. Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- +56.0%Entry HK$1.00 · Close at T+365 HK$1.56
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 57,750 sharesShareXHKGHKEX:DA20261029E00596
- 128,810 sharesShareXHKGHKEX:DA20261029E00612
- 125,228 sharesShareXHKGHKEX:DA20261029E00613
- 2,122,500 sharesShareXHKGHKEX:DA20261029E00614Canonical exit: 6 Jan 2027 (T+90)
- 33,500 shares@ HK$0.96ShareXHKGHKEX:DA20261030E00307
- 82,000 sharesShareXHKGHKEX:DA20261029E00597
- 928,000 sharesShareXHKGHKEX:DA20261029E00595Canonical exit: 6 Jan 2027 (T+90)
- 43,500 shares@ HK$0.850.0057% mcap96.4% of flowShareXHKGHKEX:DA20260924E00448
- 60,828 sharesShareXHKGHKEX:DA20260923E00600
- 285,375 sharesShareXHKGHKEX:DA20260922E00476
- 1,500 shares@ HK$0.9550.0002% mcap3.6% of flowShareXHKGHKEX:DA20260828E00313
- 65,033 sharesShareXHKGHKEX:DA20260826E00418
- 36,125 sharesShareXHKGHKEX:DA20260826E00311
- 20,500 sharesShareXHKGHKEX:DA20251103E00021
- 124,775 sharesShareXHKGHKEX:DA20251030E00479
- 2,097,500 sharesShareXHKGHKEX:DA20251030E00478Canonical exit: 26 Jan 2026 (T+90)
- 57,750 sharesShareXHKGHKEX:DA20251029E00209
- 1,044,000 sharesShareXHKGHKEX:DA20251029E00210Canonical exit: 26 Jan 2026 (T+90)
- 72,500 shares@ HK$1.8730.9% of flowShareXHKGHKEX:DA20250928E00025
- 60,603 sharesShareXHKGHKEX:DA20250924E00089
- 285,375 sharesShareXHKGHKEX:DA20250923E00011
- 32,441 sharesShareXHKGHKEX:DA20250923E00199
- 20,250 sharesShareXHKGHKEX:DA20250918E00055
- 109,000 sharesShareXHKGHKEX:DA20250911E00070
- 2,500 shares@ HK$1.881.1% of flowShareXHKGHKEX:DA20250911E00080
25 of 103 declarations
About Brii Biosciences Ltd. - B
Brii Biosciences Ltd. - B is a biopharmaceutical company focused on developing innovative treatments for infectious diseases and public health-related disorders. It is committed to improving patient lives through advanced therapeutic solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
